(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 20.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Zymeworks's revenue in 2025 is $93,384,000.On average, 5 Wall Street analysts forecast ZYME's revenue for 2025 to be $9,243,933,315, with the lowest ZYME revenue forecast at $5,673,629,919, and the highest ZYME revenue forecast at $13,950,635,098. On average, 5 Wall Street analysts forecast ZYME's revenue for 2026 to be $10,770,001,790, with the lowest ZYME revenue forecast at $3,038,200,251, and the highest ZYME revenue forecast at $21,829,747,539.
In 2027, ZYME is forecast to generate $11,027,133,875 in revenue, with the lowest revenue forecast at $3,344,807,616 and the highest revenue forecast at $14,963,833,072.